MX336187B - Metodo para tratar el mal de parkinson. - Google Patents
Metodo para tratar el mal de parkinson.Info
- Publication number
- MX336187B MX336187B MX2012010161A MX2012010161A MX336187B MX 336187 B MX336187 B MX 336187B MX 2012010161 A MX2012010161 A MX 2012010161A MX 2012010161 A MX2012010161 A MX 2012010161A MX 336187 B MX336187 B MX 336187B
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- amount ranging
- carbidopa
- inhibitor
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31039810P | 2010-03-04 | 2010-03-04 | |
| US41282110P | 2010-11-12 | 2010-11-12 | |
| US201161438416P | 2011-02-01 | 2011-02-01 | |
| PCT/FI2011/000013 WO2011107653A2 (en) | 2010-03-04 | 2011-03-03 | Method for treating parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012010161A MX2012010161A (es) | 2012-10-03 |
| MX336187B true MX336187B (es) | 2016-01-07 |
Family
ID=44065577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012010161A MX336187B (es) | 2010-03-04 | 2011-03-03 | Metodo para tratar el mal de parkinson. |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20130137729A1 (enExample) |
| EP (1) | EP2542220B1 (enExample) |
| JP (2) | JP5774610B2 (enExample) |
| KR (1) | KR101868326B1 (enExample) |
| CN (1) | CN102781424B (enExample) |
| AU (1) | AU2011222856B2 (enExample) |
| BR (1) | BR112012018256A8 (enExample) |
| CA (1) | CA2784819C (enExample) |
| EA (1) | EA026419B1 (enExample) |
| ES (1) | ES2614179T3 (enExample) |
| IL (1) | IL221744A (enExample) |
| MX (1) | MX336187B (enExample) |
| WO (1) | WO2011107653A2 (enExample) |
| ZA (1) | ZA201205836B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1907382T3 (pl) | 2005-07-26 | 2016-01-29 | Bial Portela & Ca Sa | Pochodne nitrokatecholowe jako inhibitory COMT |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| BRPI0721213B1 (pt) | 2007-01-31 | 2021-11-09 | Bial - Portela & Ca, S.A. | Uso de nitrocatecóis substituídos, e embalagem |
| WO2009116882A1 (en) | 2008-03-17 | 2009-09-24 | Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
| EA026419B1 (ru) * | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2012147099A1 (en) * | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| JP6456143B2 (ja) | 2011-12-13 | 2019-01-23 | ノヴィファーマ，エス．アー． | カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 |
| CA3178035A1 (en) * | 2012-12-24 | 2014-07-03 | Neurogastrx, Inc. | Methods for treating gi tract disorders |
| US9642810B2 (en) | 2013-03-15 | 2017-05-09 | Mylan Inc. | Formulation containing carbidopa, levodopa, and entacapone |
| EP2799065A1 (en) * | 2013-04-30 | 2014-11-05 | Deva Holding Anonim Sirketi | Levodopa carbidopa entacapone pharmaceutical formulations |
| US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| PT3341380T (pt) * | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
| EP3768263B1 (en) | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| BR112021009353A2 (pt) | 2018-11-15 | 2021-11-23 | Abbvie Inc | Formulações farmacêuticas para administração subcutânea |
| CN112741808B (zh) * | 2019-10-29 | 2024-02-06 | 南京济群医药科技股份有限公司 | 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法 |
| US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
| WO2021207634A1 (en) * | 2020-04-10 | 2021-10-14 | Senda Biosciences, Inc. | Biomarkers related to parkinson's disease and methods of using the same |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
| GB202212082D0 (en) * | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| KR102903389B1 (ko) * | 2022-11-30 | 2025-12-23 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3462536A (en) | 1960-07-22 | 1969-08-19 | Merck & Co Inc | Method of inhibiting decarboxylase |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| JPH02138A (ja) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | Ｌ‐ドーパ誘導体 |
| GB2238047B (en) | 1989-11-03 | 1993-02-10 | Orion Yhtymae Oy | Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation |
| US5607969A (en) | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
| WO2005063696A2 (de) | 2003-12-31 | 2005-07-14 | Cilag Ag | Neue kristalline formen von entacapone und deren herstellung |
| PT1751087E (pt) | 2004-06-04 | 2012-09-10 | Xenoport Inc | Derivados de levodopa e as suas composições e utilizações |
| WO2006037061A2 (en) * | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| PL1896006T3 (pl) | 2005-06-08 | 2010-03-31 | Orion Corp | Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego |
| MY148644A (en) | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
| PL1907382T3 (pl) * | 2005-07-26 | 2016-01-29 | Bial Portela & Ca Sa | Pochodne nitrokatecholowe jako inhibitory COMT |
| US7563821B2 (en) | 2005-12-05 | 2009-07-21 | Xenoport, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| US8741342B2 (en) | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| MX2010009043A (es) | 2008-02-28 | 2010-10-25 | Bial Portela & Ca Sa | Composicion farmaceutica para farmacos poco solubles. |
| UA102111C2 (uk) * | 2008-08-22 | 2013-06-10 | Вокхардт Рісерч Сентер | Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі |
| CA2734972C (en) * | 2008-08-22 | 2017-03-28 | Wockhardt Research Centre | An extended release pharmaceutical composition of entacapone or salts thereof |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| EP2233131A1 (en) | 2009-03-23 | 2010-09-29 | Laboratorios Lesvi, S.L. | Pharmaceutical composition containing levodopa, entacapone and carbidopa |
| EA026419B1 (ru) * | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| JP5551001B2 (ja) | 2010-06-22 | 2014-07-16 | 株式会社Ｐｆｕ | 摩擦係数推定装置および摩擦係数推定方法 |
| JP2015006373A (ja) * | 2014-07-14 | 2015-01-15 | 株式会社大都技研 | 遊技台 |
-
2011
- 2011-03-03 EA EA201290865A patent/EA026419B1/ru not_active IP Right Cessation
- 2011-03-03 US US13/582,427 patent/US20130137729A1/en not_active Abandoned
- 2011-03-03 BR BR112012018256A patent/BR112012018256A8/pt not_active IP Right Cessation
- 2011-03-03 JP JP2012555453A patent/JP5774610B2/ja active Active
- 2011-03-03 CN CN201180012312.9A patent/CN102781424B/zh active Active
- 2011-03-03 EP EP11709446.6A patent/EP2542220B1/en active Active
- 2011-03-03 AU AU2011222856A patent/AU2011222856B2/en active Active
- 2011-03-03 KR KR1020127025501A patent/KR101868326B1/ko active Active
- 2011-03-03 CA CA2784819A patent/CA2784819C/en active Active
- 2011-03-03 ES ES11709446.6T patent/ES2614179T3/es active Active
- 2011-03-03 MX MX2012010161A patent/MX336187B/es unknown
- 2011-03-03 WO PCT/FI2011/000013 patent/WO2011107653A2/en not_active Ceased
-
2012
- 2012-08-02 ZA ZA2012/05836A patent/ZA201205836B/en unknown
- 2012-09-02 IL IL221744A patent/IL221744A/en active IP Right Grant
-
2014
- 2014-10-02 US US14/504,925 patent/US10857120B2/en active Active
-
2015
- 2015-05-01 JP JP2015094429A patent/JP2015180644A/ja active Pending
-
2020
- 2020-10-07 US US17/064,759 patent/US11771675B2/en active Active
-
2023
- 2023-08-25 US US18/455,759 patent/US12521363B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011222856B2 (en) | 2015-10-15 |
| HK1177896A1 (zh) | 2013-08-30 |
| EP2542220B1 (en) | 2016-11-02 |
| MX2012010161A (es) | 2012-10-03 |
| BR112012018256A8 (pt) | 2017-12-19 |
| US12521363B2 (en) | 2026-01-13 |
| JP5774610B2 (ja) | 2015-09-09 |
| WO2011107653A3 (en) | 2011-11-03 |
| CA2784819C (en) | 2018-02-13 |
| KR20130006638A (ko) | 2013-01-17 |
| AU2011222856A1 (en) | 2012-07-26 |
| EA026419B1 (ru) | 2017-04-28 |
| WO2011107653A2 (en) | 2011-09-09 |
| IL221744A (en) | 2016-11-30 |
| ZA201205836B (en) | 2014-01-29 |
| US20210085635A1 (en) | 2021-03-25 |
| EP2542220A2 (en) | 2013-01-09 |
| US20150150839A1 (en) | 2015-06-04 |
| ES2614179T3 (es) | 2017-05-30 |
| US11771675B2 (en) | 2023-10-03 |
| JP2013521263A (ja) | 2013-06-10 |
| US20130137729A1 (en) | 2013-05-30 |
| US20240050394A1 (en) | 2024-02-15 |
| EA201290865A1 (ru) | 2013-02-28 |
| BR112012018256A2 (enExample) | 2011-09-09 |
| US10857120B2 (en) | 2020-12-08 |
| JP2015180644A (ja) | 2015-10-15 |
| WO2011107653A8 (en) | 2012-08-02 |
| CA2784819A1 (en) | 2011-09-09 |
| CN102781424B (zh) | 2016-03-30 |
| CN102781424A (zh) | 2012-11-14 |
| KR101868326B1 (ko) | 2018-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012010161A (es) | Metodo para tratar el mal de parkinson. | |
| ECSP19043725A (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| CO6640206A2 (es) | Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo | |
| DOP2017000105A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| BR112014008036A2 (pt) | tratamento de rinite | |
| NZ713202A (en) | Diagnosis and treatments relating to th2 inhibition | |
| MX360289B (es) | Composiciones de tapentadol. | |
| MX350046B (es) | Tratamientos para trastornos gastrointestinales. | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MX2019009244A (es) | FORMULACION PARA ANTICUERPO ANTI -A4ß7. | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| BR112015010396A2 (pt) | terapia de combinação | |
| BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| MX344476B (es) | Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal. | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| CO6640335A2 (es) | Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| AR124078A1 (es) | Método para el tratamiento de la enfermedad de parkinson | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| AR075041A1 (es) | Composicion farmaceutica que contiene aleglitazar, proceso, uso. | |
| UY31826A (es) | Compuesto peptídico y su uso |